英特格拉生命科学
IART
13.21
-0.32
-2.37%
英特格拉生命科学
US · IART
#3240 按市值排名
13.21
-0.32
-2.37%
实时 - 追踪5344个代码 - 心跳于46秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 106.73% +0.22pp
- 机构数量
- 258
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund74.24%
Hedge Fund15.96%
Private Company11.52%
Individual/Insider3.63%
Public Company3.26%
Government Pension Fund1.33%
Insurance Company0.32%
主要股东 截至 2026-06-30
BlackRock
13.74% · 10.68M 股
Tru St Partnership LP
10.95% · 8.52M 股
Rubric Capital Management LP
9.97% · 7.75M 股
Vanguard Portfolio Management, LLC
4.81% · 3.74M 股
Invesco Ltd.
4.43% · 3.44M 股
Paradigm Capital Management, Inc.
4.42% · 3.44M 股
Fuller & Thaler Asset Management, Inc.
4.42% · 3.44M 股
Vanguard Capital Management, LLC
4.36% · 3.39M 股
Eaton Vance Management
4.15% · 3.23M 股
State Street Global Advisors
3.79% · 2.95M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 30次买入 · 19次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Tru St Partnership LP | -- | 10.95% |
| Stuart Essig | Independent Chairperson | 2.30% |
| Barbara Hill | Independent Director | 0.24% |
| Mojdeh Poul | Chief Executive Officer | 0.13% |
| Christian Schade | Independent Director | 0.12% |
| Keith N. Bradley | Independent Director | 0.11% |
| Raymond Murphy | Independent Director | 0.11% |
| Robert Davis | Executive VP & President of Tissue Technologies | 0.09% |
| Michael McBreen | Executive VP & President of Codman Specialty Surgical | 0.08% |
| Eric Schwartz | Executive Vice President | 0.07% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-16 | Lesha Shinn | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-08-31 | Chantal Veillon-Berteloot | Executive Vice President | Sale to Issuer | -1,455 | $16.62 |
| 2026-07-02 | Lea Knight | Chief Financial Officer | Sale to Issuer | -5,226 | $18.05 |
| 2026-06-30 | Robert Davis | Executive VP & President of Tissue Technologies | Other Derivative Acquisition | +11,180 | -- |
| 2026-06-30 | Jeffrey Mosebrook | Senior VP & PAO | Sale to Issuer | -937 | $17.89 |
| 2026-06-30 | Harvinder Singh | Executive VP & President of International Business | Other Derivative Acquisition | +5,590 | -- |
| 2026-05-31 | Stuart Essig | Independent Chairperson | Other Derivative Acquisition | +365,297 | -- |
| 2026-05-31 | Stuart Essig | Independent Chairperson | Other Derivative Acquisition | +705,468 | $15.67 |
| 2026-05-31 | Michael McBreen | Executive VP & President of Codman Specialty Surgical | Other Derivative Acquisition | +31,909 | -- |
| 2026-05-31 | Michael McBreen | Executive VP & President of Codman Specialty Surgical | Other Derivative Acquisition | +60,372 | $15.67 |
| 2026-05-08 | Keith N. Bradley | Independent Director | Sale to Issuer | -882 | $13.92 |
| 2026-05-06 | Christian Schade | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Barbara Hill | Independent Director | Other Acquisition | +24,338 | -- |
| 2026-05-06 | Keith N. Bradley | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Jeffrey Graves | Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Shaundra Clay | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-05-06 | Renee Lo | Independent Director | Other Derivative Acquisition | +17,700 | -- |
| 2026-03-10 | Robert Davis | Executive VP & President of Tissue Technologies | Sale to Issuer | -9,174 | $9.55–9.61 |
| 2026-03-10 | Robert Davis | Executive VP & President of Tissue Technologies | Other Derivative Acquisition | +43,350 | -- |
| 2026-03-10 | Mojdeh Poul | Chief Executive Officer | Other Derivative Acquisition | +343,393 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
英特格拉生命科学 讨论区 0 条评论